focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
Well well, swazer, you have deleted yet another post midnight rant, but not before I reported it for being grossly offensive. See para 4 of rules before posting; you seem to have ticked most of the boxes. Just to remind you, you posted it at 01.47 am on Sunday morning, and I have copied it.
Meanwhile please provide evidence for your unpleasant assertions, and I quote you: a) that all of my posts on PHE are a deramp, b) that my agenda is to make folks poor etc,. c) that I am not a genuine investor d) that many of my posts are lies, misinformation.
I fear that your messianic fervour to expose 'asshats' may have got the better of your judgement on this occasion.
BMN
Sorry, I was being a tad flippant. Hydrogen certainly not for all means of transport. But PHE in a sweet spot IF, and only if the H2OZ story turns out to be real. I think there is a lot of overpromising in the H2OZ release, and investors in PHE been there before.......
"Powerhouse Energy Group (LON:PHE) is National H2’s exclusive technology provider and will play a crucial role in developing the waste-to-energy plants across the APAC region. Listed on the London Stock Exchange"
Dr A. I find the gap between this confident statement in the National H2 release and the radio silence back in the UK very odd. Could National H2 be overegging the status of the agreement?
swazer
It was a reasonable speculation on the basis that PHE had not yet confirmed anything. And I half expected another rant from you. Remember the one timed at 00.18h a week or two back that you deleted, when I pointed out that post midnight rants are rarely helpful? And now you are at it in the daytime as well. If you have anger issues there are folk who might be able to help you. I am not alone on this board in finding your posts unpleasant. Please go away and stay away in the absence of any useful contribution.
Jelenko
I do not understand you. Parsortix does not 'capture' cDNA, that is, tumour DNA fragments in plasma. Period. in order to extract and use cDNA from plasma is a highly complex process being used and refined by several American companies. Parsortix can capture CTCs by a clever microfluidic process. i accept that the plasma from a single blood sample used for Parsortix could also be used to search for cDNA, but capturing TCs and extracting cDNA from plasma are entirely separate processes. AGL per se is not in the business of extracting cDNA.
What I was trying to get at is whether there is enough information available from cDNA for clinical decisions to be made reliably and reproduceably. This is what the present Marsden study seeks to determine.
Please tell us what research you relied on to make the statement "Parsortix captures CtDNA if required"
The basic question for me is: what advantages does the capture of CTCs over circulating DNA (cDNA) ? How reliable is extraction of cDNA, and how consistently can one detect it in blood of patients with residual tumour (which is what the study from the Marsden is about). If it provides enough info for an informed treatment decision to be made, and cDNA can be extracted more consistently than capture of CTCs, then AGL is in deep trouble.
Parsortix is the Roll-Royce of tumour cell analysis, but if capture rates are significantly lower than rates for extraction of cDNA, or if enough info can be consistently extracted from cDNA then a Rolls may be redundant. As an LTH, I hope not, but am far from happy with the present state of AGL
In the Newsletter I don't think he meant 'where it can pull a big punch'; sounds good but means the opposite to what he intended! It means to strike a blow less powerful or forceful than it could be. Oh dear.